Moderna to Host Investor Event - R&D Day and Business Updates
Moderna (Nasdaq: MRNA) has announced an upcoming Investor Event - R&D Day and Business Updates scheduled for September 12, 2024 at 9:00 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Moderna (Nasdaq: MRNA) has announced an upcoming Investor Event - R&D Day and Business Updates scheduled for September 12, 2024 at 9:00 a.m. ET. This event will feature presentations from the company's management team, focusing on Moderna's development and commercial strategy, as well as key business considerations.
Investors and interested parties can access a live webcast of the presentation through the 'Events and Presentations' section of Moderna's investor relations website. For those unable to attend the live event, a replay of the webcast will be available on the company's website for at least 30 days following the presentation, ensuring widespread access to this important corporate update.
Details
News Market Reaction – MRNA
The recorded move for MRNA in the trading session of this news was -6.47%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, MA / ACCESSWIRE / August 22, 2024 / Moderna, Inc. (Nasdaq:MRNA) today announced that it will host its Investor Event - R&D Day and Business Updates at 9:00 a.m. ET on Thursday, September 12, 2024.
The event will include presentations from management discussing Moderna's development and commercial strategy and key business considerations. A live webcast of the presentation will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com. A replay of the webcast will be archived on Moderna's website for at least 30 days following the presentation.
About Moderna
Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.
Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
Lavina.Talukdar@modernatx.com
SOURCE: Moderna, Inc.
View the original press release on accesswire.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.